An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of the long-term use of pregabalin at doses
up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain,
post stroke pain, and multiple sclerosis pain).
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.